New therapies for hepatitis C virus infection

Jennifer L. Horsley-Silva, Hugo E Vargas

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or liver failure. Recently, vast improvements have been made with the development of direct-acting antiviral (DAA) agents, which are all-oral, are better tolerated than interferon-based treatment, and provide a sustained virologic response in more than 90% of treated patients. This article reviews the new therapies available for HCV infection, with a focus on patients who have chronic HCV with and without compensated cirrhosis. As DAA development continues, more attention will need to be given to special patient populations, specifically to patients who fail treatment due to emerging resistant strains. Considerable challenges yet to be overcome are incremental diagnosis of unidentified patients and linkage to care that is affordable and available to all patients.

Original languageEnglish (US)
Pages (from-to)22-31
Number of pages10
JournalGastroenterology and Hepatology
Volume13
Issue number1
StatePublished - Jan 1 2017

Fingerprint

Virus Diseases
Hepacivirus
Antiviral Agents
Fibrosis
Therapeutics
Liver Failure
Chronic Hepatitis C
Interferons
Hepatocellular Carcinoma
Morbidity
Mortality
Population

Keywords

  • Cirrhosis
  • Direct-acting antiviral agents
  • Hepatitis C virus
  • Sustained virologic response

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

New therapies for hepatitis C virus infection. / Horsley-Silva, Jennifer L.; Vargas, Hugo E.

In: Gastroenterology and Hepatology, Vol. 13, No. 1, 01.01.2017, p. 22-31.

Research output: Contribution to journalReview article

Horsley-Silva, Jennifer L. ; Vargas, Hugo E. / New therapies for hepatitis C virus infection. In: Gastroenterology and Hepatology. 2017 ; Vol. 13, No. 1. pp. 22-31.
@article{700c8c98e5df48909ad1795ba3642f60,
title = "New therapies for hepatitis C virus infection",
abstract = "Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or liver failure. Recently, vast improvements have been made with the development of direct-acting antiviral (DAA) agents, which are all-oral, are better tolerated than interferon-based treatment, and provide a sustained virologic response in more than 90{\%} of treated patients. This article reviews the new therapies available for HCV infection, with a focus on patients who have chronic HCV with and without compensated cirrhosis. As DAA development continues, more attention will need to be given to special patient populations, specifically to patients who fail treatment due to emerging resistant strains. Considerable challenges yet to be overcome are incremental diagnosis of unidentified patients and linkage to care that is affordable and available to all patients.",
keywords = "Cirrhosis, Direct-acting antiviral agents, Hepatitis C virus, Sustained virologic response",
author = "Horsley-Silva, {Jennifer L.} and Vargas, {Hugo E}",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
volume = "13",
pages = "22--31",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - New therapies for hepatitis C virus infection

AU - Horsley-Silva, Jennifer L.

AU - Vargas, Hugo E

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or liver failure. Recently, vast improvements have been made with the development of direct-acting antiviral (DAA) agents, which are all-oral, are better tolerated than interferon-based treatment, and provide a sustained virologic response in more than 90% of treated patients. This article reviews the new therapies available for HCV infection, with a focus on patients who have chronic HCV with and without compensated cirrhosis. As DAA development continues, more attention will need to be given to special patient populations, specifically to patients who fail treatment due to emerging resistant strains. Considerable challenges yet to be overcome are incremental diagnosis of unidentified patients and linkage to care that is affordable and available to all patients.

AB - Approximately 350 million people worldwide are infected with hepatitis C virus (HCV), which is associated with morbidity and mortality related to cirrhosis, hepatocellular carcinoma, or liver failure. Recently, vast improvements have been made with the development of direct-acting antiviral (DAA) agents, which are all-oral, are better tolerated than interferon-based treatment, and provide a sustained virologic response in more than 90% of treated patients. This article reviews the new therapies available for HCV infection, with a focus on patients who have chronic HCV with and without compensated cirrhosis. As DAA development continues, more attention will need to be given to special patient populations, specifically to patients who fail treatment due to emerging resistant strains. Considerable challenges yet to be overcome are incremental diagnosis of unidentified patients and linkage to care that is affordable and available to all patients.

KW - Cirrhosis

KW - Direct-acting antiviral agents

KW - Hepatitis C virus

KW - Sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=85010927992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010927992&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85010927992

VL - 13

SP - 22

EP - 31

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 1

ER -